Literature DB >> 27806876

Chorea and parkinsonism associated with autoantibodies to IgLON5 and responsive to immunotherapy.

Ren Haitao1, Yang Yingmai1, Huang Yan1, Han Fei1, Lv Xia1, Hao Honglin1, Liu Chaiyan1, Winfried Stöcker2, Cui Liying3, Guan Hongzhi4.   

Abstract

Encephalopathy associated with autoantibodies to IgLON5 is a novel syndrome characterized by a distinct sleep disorder and brain-stem involvement. Since the initial description of this encephalopathy in 2014, only a few additional patients have been reported (Simabukuro et al., 2015). In this paper, we report a new case of anti-IgLON5 antibodies with major symptoms of chorea and parkinsonism, and responsive to immunotherapy.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27806876     DOI: 10.1016/j.jneuroim.2016.09.012

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  17 in total

Review 1.  The Sleep Disorder in Anti-lgLON5 Disease.

Authors:  Carles Gaig; Alex Iranzo; Joan Santamaria; Francesc Graus
Journal:  Curr Neurol Neurosci Rep       Date:  2018-05-23       Impact factor: 5.081

2.  Intravenous immunoglobulins as first-line therapy for IgLON5 encephalopathy.

Authors:  K Logmin; A S Moldovan; S Elben; A Schnitzler; S J Groiss
Journal:  J Neurol       Date:  2019-02-08       Impact factor: 4.849

3.  Antibody-associated CNS syndromes without signs of inflammation in the elderly.

Authors:  Domingo Escudero; Mar Guasp; Helena Ariño; Carles Gaig; Eugenia Martínez-Hernández; Josep Dalmau; Francesc Graus
Journal:  Neurology       Date:  2017-09-06       Impact factor: 9.910

Review 4.  Sleep and neurological autoimmune diseases.

Authors:  Alex Iranzo
Journal:  Neuropsychopharmacology       Date:  2019-07-14       Impact factor: 7.853

5.  Frequency and Characterization of Movement Disorders in Anti-IgLON5 Disease.

Authors:  Carles Gaig; Yaroslau Compta; Anna Heidbreder; Maria J Marti; Maarten J Titulaer; Yvette Crijnen; Birgit Högl; Jan Lewerenz; María Elena Erro; Juan Carlos Garcia-Monco; Pasquale Nigro; Nicola Tambasco; Maja Patalong-Ogiewa; Marcus Erdler; Stefan Macher; Evelyn Berger-Sieczkowski; Romana Höftberger; Christian Geis; Markus Hutterer; Angela Milán-Tomás; Antonio Martin-Bastida; Lydia Lopez Manzanares; Sonia Quintas; Günter U Höglinger; Nora Möhn; Florian Schoeberl; Franziska S Thaler; Gian Maria Asioli; Federica Provini; Giuseppe Plazzi; Koldo Berganzo; Morten Blaabjerg; Norbert Brüggemann; Tarsis Farias; Chen Fei Ng; Caroline Giordana; Alejandro Herrero-San Martín; Lucio Huebra; Katya Kotschet; Herburg Liendl; Teresa Montojo; Carlos Morata; Jesus Perez Perez; Inmaculada Puertas; Thomas Seifert-Held; Caspar Seitz; Mateus Mistieri Simabukuro; Nieves Tellez; Javier Villacieros-Álvarez; Barbara Willekens; Lidia Sabater; Alex Iranzo; Joan Santamaria Cano; Josep Dalmau; Francesc Graus
Journal:  Neurology       Date:  2021-08-11       Impact factor: 11.800

Review 6.  Anti-IgLON 5 Disease.

Authors:  Anna Heidbreder; Konstanze Philipp
Journal:  Curr Treat Options Neurol       Date:  2018-06-23       Impact factor: 3.598

7.  IgLON5 disease responsive to immunotherapy.

Authors:  Michael Bonello; Anu Jacob; Mark A Ellul; Erandi Barker; Robert Parker; Samantha Jefferson; Sundus Alusi
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2017-08-07

Review 8.  A New Classification System for IgG4 Autoantibodies.

Authors:  Inga Koneczny
Journal:  Front Immunol       Date:  2018-02-12       Impact factor: 7.561

9.  IgLON5 antibody: Neurological accompaniments and outcomes in 20 patients.

Authors:  Josephe A Honorat; Lars Komorowski; Keith A Josephs; Kai Fechner; Erik K St Louis; Shannon R Hinson; Sabine Lederer; Neeraj Kumar; Avi Gadoth; Vanda A Lennon; Sean J Pittock; Andrew McKeon
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2017-07-18

10.  IgLON5-Associated Encephalitis With Atypical Brain Magnetic Resonance Imaging and Cerebrospinal Fluid Changes.

Authors:  Massimiliano Montagna; Rizvana Amir; Ilse De Volder; Martin Lammens; Jef Huyskens; Barbara Willekens
Journal:  Front Neurol       Date:  2018-05-17       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.